Furthermore, and as discussed, information is now available showing positive clinical trial data with the SGLT-2 inhibitors (gliflozins) and GLP-1 RAs and their CV protective benefits in patients with T2D, and like metformin, their use in non-diabetic populations is being considered. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.